Shanghai Henlius Biotech
Clinical trials sponsored by Shanghai Henlius Biotech, explained in plain language.
-
New hope for lung cancer patients: drug combo may extend survival
Disease control OngoingThis study tests whether adding the drug serplulimab to standard chemotherapy and radiation helps people with limited-stage small cell lung cancer live longer without their cancer growing. About 511 adults with this type of lung cancer will take part. The goal is to see if the ne…
Phase: PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 26, 2026 08:40 UTC
-
New drug combo shows promise for tough lung cancer
Disease control OngoingThis study tests a new immunotherapy drug (HLX10) combined with standard chemotherapy in 26 Japanese patients with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if the combination shrinks tumors and improves survival. Researchers will…
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 26, 2026 08:35 UTC
-
New lung cancer drug combo aims to outperform current standard
Disease control OngoingThis study tests a new drug, serplulimab, combined with chemotherapy, against the current standard treatment (atezolizumab plus chemo) for people with extensive-stage small cell lung cancer who have not had prior treatment. About 200 participants will be randomly assigned to one …
Phase: PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 26, 2026 08:30 UTC